Literature DB >> 8309583

Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction.

C Malapani1, B Pillon, B Dubois, Y Agid.   

Abstract

Patients with Parkinson's disease (PD) have trouble programming two separate motor acts concurrently. We tested the hypotheses that (1) PD patients may also have difficulty processing two cognitive tasks simultaneously, and (2) the expected deficit may be related to the striatal dopaminergic depletion. We used auditory and visual choice reaction time (CRT) tasks, presented either separately or concurrently, and compared the performance of three groups of PD patients: a group of patients under their usual dose of levodopa ("standard"); a group assessed both at the time of maximal clinical benefit ("on" state) and at the time of minimal clinical benefit (treatment withdrawn for about 18 hours; "off" state); and a group of recently diagnosed untreated patients ("de novo"). Compared with controls, standard and "on" state patients had a normal performance for both separate and concurrent CRT tasks. In contrast, "off" state and de novo patients had a normal performance in the separate CRT tasks but significant deficits in the concurrent CRT tasks. These results suggest that adequate dopaminergic transmission is necessary for concurrent processing of cognitive information and that the striatum integrates the sensorimotor information required to program cognitive acts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8309583     DOI: 10.1212/wnl.44.2.319

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Cognitive improvement during Tolcapone treatment in Parkinson's disease.

Authors:  M Gasparini; E Fabrizio; V Bonifati; G Meco
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients.

Authors:  Kathy Dujardin; Luc Defebvre; Alain Duhamel; Pascal Lecouffe; Pascal Rogelet; Marc Steinling; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

4.  Simultaneous Voltammetric Measurements of Glucose and Dopamine Demonstrate the Coupling of Glucose Availability with Increased Metabolic Demand in the Rat Striatum.

Authors:  Samantha K Smith; Christie A Lee; Matthew E Dausch; Brian M Horman; Heather B Patisaul; Gregory S McCarty; Leslie A Sombers
Journal:  ACS Chem Neurosci       Date:  2017-01-17       Impact factor: 4.418

Review 5.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

6.  Memory impairment in Parkinson's disease.

Authors:  V V Zakharov; T V Akhutina; N N Yakhno
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

7.  Leakage of decision uncertainty into movement execution in Parkinson's disease?

Authors:  Peter Praamstra; Andrea F Loing; Floris P de Lange
Journal:  Exp Brain Res       Date:  2013-10-05       Impact factor: 1.972

8.  Closed head injury and perceptual processing in dual-task situations.

Authors:  G Hein; T Schubert; D Y von Cramon
Journal:  Exp Brain Res       Date:  2004-08-24       Impact factor: 1.972

Review 9.  Pharmacological manipulation of human working memory.

Authors:  Deanna M Barch
Journal:  Psychopharmacology (Berl)       Date:  2004-01-30       Impact factor: 4.530

10.  Neuropsychological functions and rCBF SPECT in Parkinson's disease patients considered candidates for deep brain stimulation.

Authors:  Anna Paschali; Lambros Messinis; Epameinondas Lyros; Costas Constantoyannis; Zinovia Kefalopoulou; Velissarios Lakiotis; Panagiotis Papathanasopoulos; Paulos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.